HDL quality in atherosclerosis: can ratios between apolipoproteins of HDL be used effectively to indicate risk of premature myocardial infarction?

Bibliography

• Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 208(1), 3–9 (2009).
   Google Scholar
• Soloff LA. Intermediate lipoproteins, atherosclerosis, and Gofman. Circulation 97(7), 708 (1998).
   Google Scholar
• Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am. J. Med. 62(5), 707–714 (1977).
   Google Scholar
• Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 104(18), 2158–2163 (2001).
   Google Scholar
• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr. Atheroscler. Rep. 14(1), 1–10 (2012).
   Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1), 8–15 (1989).
   Google Scholar
• Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case–control study. Lancet 1(8019), 965–968 (1977).
   Google Scholar
• Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham heart study. Arteriosclerosis 8(6), 737–741 (1988).
   Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109–2122 (2007).
   Google Scholar
• McQueen MJ, Hawken S, Wang X et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the Interheart study): a case–control study. Lancet 372(9634), 224–233 (2008).
   Google Scholar
• Walldius G, Jungner I. Apolipoprotein A?I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr. Opin. Cardiol. 22(4), 359–367 (2007).
   Google Scholar
• Parish S, Peto R, Palmer A et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur. Heart J. 30(17), 2137–2146 (2009).
   Google Scholar
• Kavo AE, Rallidis LS, Sakellaropoulos GC et al. Qualitative characteristics of HDL in young patients of an acute myocardial infarction. Atherosclerosis 220(1), 257–264 (2012).
   Google Scholar
• Marcel YL, Weech PK, Nguyen TD, Milne RW, McConathy WJ. Apolipoproteins as the basis for heterogeneity in high-density lipoprotein 2 and high-density lipoprotein 3. Studies by isoelectric focusing on agarose films. Eur. J. Biochem. 143(3), 467–476 (1984).
   Google Scholar
• Asztalos BF, Roheim PS, Milani RL et al. Distribution of ApoA?I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20(12), 2670–2676 (2000).
   Google Scholar
• Kypreos KE, Zannis VI. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem. J. 403(2), 359–367 (2007).
   Google Scholar
• Kypreos KE. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia. Biochemistry 47(39), 10491–10502 (2008).
   Google Scholar
• Huang R, Silva RA, Jerome WG et al. Apolipoprotein A?I structural organization in high-density lipoproteins isolated from human plasma. Nat. Struct. Mol. Biol. 18(4), 416–422 (2012).
   Google Scholar
• Segrest JP, Jones MK, Klon AE et al. A detailed molecular belt model for apolipoprotein A?I in discoidal high density lipoprotein. J. Biol. Chem. 274(45), 31755–31758 (1999).
   Google Scholar